Pazopanib (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Pazopanib" in English language version.

refsWebsite

Global rank English rank

11nih.gov

4^th place

7doi.org

2^nd place

4web.archive.org

1^st place

3semanticscholar.org

11^th place

8^th place

2europa.eu

68^th place

117^th place

1medscape.com

719^th place

636^th place

1medicines.org.uk

3,823^rd place

2,387^th place

1tga.gov.au

3,984^th place

2,622^nd place

1pbs.gov.au

low place

1pharmac.govt.nz

low place

1fiercebiotech.com

low place

8,828^th place

1reuters.com

49^th place

47^th place

1gsk.com

low place

1onclive.com

low place

doi.org

Mangla A, Agarwal N, Schwartz G (February 2024). "Desmoid Tumors: Current Perspective and Treatment". Current Treatment Options in Oncology. 25 (2): 161–175. doi:10.1007/s11864-024-01177-5. PMC 10873447. PMID 38270798.
Zivi A, Cerbone L, Recine F, Sternberg CN (September 2012). "Safety and tolerability of pazopanib in the treatment of renal cell carcinoma". Expert Opinion on Drug Safety. 11 (5): 851–859. doi:10.1517/14740338.2012.712108. PMID 22861374. S2CID 2178331.
Khurana V, Minocha M, Pal D, Mitra AK (March 2014). "Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors". Drug Metabolism and Drug Interactions. 29 (3): 179–190. doi:10.1515/dmdi-2013-0062. PMC 4407685. PMID 24643910.
Khurana V, Minocha M, Pal D, Mitra AK (May 2014). "Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors". Drug Metabolism and Drug Interactions. 29 (4): 249–259. doi:10.1515/dmdi-2014-0014. PMC 4407688. PMID 24807167.
Verweij J, Sleijfer S (May 2013). "Pazopanib, a new therapy for metastatic soft tissue sarcoma". Expert Opinion on Pharmacotherapy. 14 (7): 929–935. doi:10.1517/14656566.2013.780030. PMID 23488774. S2CID 5063031.
Schöffski P (June 2012). "Pazopanib in the treatment of soft tissue sarcoma". Expert Review of Anticancer Therapy. 12 (6): 711–723. doi:10.1586/era.12.41. PMID 22716487. S2CID 1738165.
Pick AM, Nystrom KK (March 2012). "Pazopanib for the treatment of metastatic renal cell carcinoma". Clinical Therapeutics. 34 (3): 511–520. doi:10.1016/j.clinthera.2012.01.014. PMID 22341567.

europa.eu

ema.europa.eu

"CHMP Assessment Report: Votrient (pazopanib)" (PDF). European Medicines Agency. Archived from the original (PDF) on 9 October 2016. Retrieved 8 October 2016.
"Votrient : EPAR - Product Information" (PDF). European Medicines Agency. Glaxo Group Ltd. 23 January 2014. Archived from the original (PDF) on 4 February 2014. Retrieved 27 January 2014.

fiercebiotech.com

"Pazopanib shows encouraging activity in several tumour types, including soft tissue sarcoma and ovarian cancer". FierceBiotech. 15 September 2008. Retrieved 10 August 2010.

gsk.com

"Regulatory update: Votrient (pazopanib) as maintenance therapy for advanced ovarian cancer in the EU". GlaxoSmithKline. 31 March 2014. Archived from the original on 8 April 2014. Retrieved 7 April 2014.

medicines.org.uk

"Votrient 200 mg and 400 mg film coated tablets - Summary of Product Characteristics (SPC)". electronic Medicines Compendium. GlaxoSmithKline UK. 20 December 2013. Retrieved 27 January 2014.

medscape.com

reference.medscape.com

"Votrient (pazopanib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 27 January 2014.

nih.gov

pubmed.ncbi.nlm.nih.gov

Mangla A, Agarwal N, Schwartz G (February 2024). "Desmoid Tumors: Current Perspective and Treatment". Current Treatment Options in Oncology. 25 (2): 161–175. doi:10.1007/s11864-024-01177-5. PMC 10873447. PMID 38270798.
Zivi A, Cerbone L, Recine F, Sternberg CN (September 2012). "Safety and tolerability of pazopanib in the treatment of renal cell carcinoma". Expert Opinion on Drug Safety. 11 (5): 851–859. doi:10.1517/14740338.2012.712108. PMID 22861374. S2CID 2178331.
Khurana V, Minocha M, Pal D, Mitra AK (March 2014). "Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors". Drug Metabolism and Drug Interactions. 29 (3): 179–190. doi:10.1515/dmdi-2013-0062. PMC 4407685. PMID 24643910.
Khurana V, Minocha M, Pal D, Mitra AK (May 2014). "Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors". Drug Metabolism and Drug Interactions. 29 (4): 249–259. doi:10.1515/dmdi-2014-0014. PMC 4407688. PMID 24807167.
Verweij J, Sleijfer S (May 2013). "Pazopanib, a new therapy for metastatic soft tissue sarcoma". Expert Opinion on Pharmacotherapy. 14 (7): 929–935. doi:10.1517/14656566.2013.780030. PMID 23488774. S2CID 5063031.
Schöffski P (June 2012). "Pazopanib in the treatment of soft tissue sarcoma". Expert Review of Anticancer Therapy. 12 (6): 711–723. doi:10.1586/era.12.41. PMID 22716487. S2CID 1738165.
Pick AM, Nystrom KK (March 2012). "Pazopanib for the treatment of metastatic renal cell carcinoma". Clinical Therapeutics. 34 (3): 511–520. doi:10.1016/j.clinthera.2012.01.014. PMID 22341567.

ncbi.nlm.nih.gov

Mangla A, Agarwal N, Schwartz G (February 2024). "Desmoid Tumors: Current Perspective and Treatment". Current Treatment Options in Oncology. 25 (2): 161–175. doi:10.1007/s11864-024-01177-5. PMC 10873447. PMID 38270798.
Khurana V, Minocha M, Pal D, Mitra AK (March 2014). "Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors". Drug Metabolism and Drug Interactions. 29 (3): 179–190. doi:10.1515/dmdi-2013-0062. PMC 4407685. PMID 24643910.
Khurana V, Minocha M, Pal D, Mitra AK (May 2014). "Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors". Drug Metabolism and Drug Interactions. 29 (4): 249–259. doi:10.1515/dmdi-2014-0014. PMC 4407688. PMID 24807167.

dailymed.nlm.nih.gov

"Votrient- pazopanib hydrochloride tablet, film coated". DailyMed. 17 August 2020. Retrieved 9 November 2020.

onclive.com

Rimel BJ (April 2015). "Antiangiogenesis agents in ovarian cancer". Contemporary Oncology. 7 (2): 16–19.

pbs.gov.au

"Pharmaceutical Benefits Scheme (PBS) - Pazopanib". Pharmaceutical Benefits Scheme. Australian Government. Retrieved 27 January 2014.

pharmac.govt.nz

"Pazopanib - Online Pharmaceutical Schedule". Pharmaceutical Management Agency. Retrieved 9 June 2015.

reuters.com

uk.reuters.com

"GSK pulls bid to extend use of kidney drug to ovarian cancer". Reuters. 31 March 2014. Archived from the original on 7 March 2016. Retrieved 7 April 2014.

semanticscholar.org

api.semanticscholar.org

Zivi A, Cerbone L, Recine F, Sternberg CN (September 2012). "Safety and tolerability of pazopanib in the treatment of renal cell carcinoma". Expert Opinion on Drug Safety. 11 (5): 851–859. doi:10.1517/14740338.2012.712108. PMID 22861374. S2CID 2178331.
Verweij J, Sleijfer S (May 2013). "Pazopanib, a new therapy for metastatic soft tissue sarcoma". Expert Opinion on Pharmacotherapy. 14 (7): 929–935. doi:10.1517/14656566.2013.780030. PMID 23488774. S2CID 5063031.
Schöffski P (June 2012). "Pazopanib in the treatment of soft tissue sarcoma". Expert Review of Anticancer Therapy. 12 (6): 711–723. doi:10.1586/era.12.41. PMID 22716487. S2CID 1738165.

tga.gov.au

ebs.tga.gov.au

"Product Information Votrient Tablets" (PDF). TGA eBusiness Services. GlaxoSmithKline Australia Pty Ltd. 25 March 2013. Retrieved 27 January 2014.

web.archive.org

"CHMP Assessment Report: Votrient (pazopanib)" (PDF). European Medicines Agency. Archived from the original (PDF) on 9 October 2016. Retrieved 8 October 2016.
"Votrient : EPAR - Product Information" (PDF). European Medicines Agency. Glaxo Group Ltd. 23 January 2014. Archived from the original (PDF) on 4 February 2014. Retrieved 27 January 2014.
"GSK pulls bid to extend use of kidney drug to ovarian cancer". Reuters. 31 March 2014. Archived from the original on 7 March 2016. Retrieved 7 April 2014.
"Regulatory update: Votrient (pazopanib) as maintenance therapy for advanced ovarian cancer in the EU". GlaxoSmithKline. 31 March 2014. Archived from the original on 8 April 2014. Retrieved 7 April 2014.